Keith D Lindor

List of Publications by Citations

280 papers	23,148 citations	84 h-index	147 g-index
300 ext. papers	26,846 ext. citations	7.2 avg, IF	6.85 L-index

#	Paper	IF	Citations
280	Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology*, **1999**, 30, 1356-62	11.2	1236
279	Primary biliary cirrhosis. *Hepatology*, **2009**, 50, 291-308	11.2	875
278	Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. *Gastroenterology*, **2008**, 134, 706-15	13.3	671
277	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. *New England Journal of Medicine*, **2016**, 375, 631-43	59.2	574
276	Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. *Hepatology*, **2004**, 39, 770-8	11.2	549
275	Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. *Gastroenterology*, **1997**, 113, 884-90	13.3	517
274	Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. *New England Journal of Medicine*, **1997**, 336, 691-5	59.2	478
273	High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. *Hepatology*, **2009**, 50, 808-14	11.2	459
272	Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. *Hepatology*, **2005**, 42, 1194-202	11.2	448
271	Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. *Gastroenterology*, **2003**, 124, 889-93	13.3	446
270	Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2004**, 99, 523-6	0.7	413
269	Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. *Gastroenterology*, **1994**, 106, 1284-90	13.3	397
268	Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. *Gastroenterology*, **2015**, 148, 751-61.e8	13.3	381
267	Primary sclerosing cholangitis. *Lancet, The*, **2013**, 382, 1587-99	40	370
266	Primary biliary cirrhosis. *Lancet, The*, **2015**, 386, 1565-75	40	325
265	Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. *Gastroenterology*, **2013**, 145, 521-36	13.3	290
264	ACG Clinical Guideline: Primary Sclerosing Cholangitis. *American Journal of Gastroenterology*, **2015**, 110, 646-59; quiz 660	0.7	280

263	Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2006**, 101, 2070-5	0.7	280
262	Epidemiology and natural history of primary biliary cirrhosis in a US community. *Gastroenterology*, **2000**, 119, 1631-6	13.3	278
261	Primary biliary cirrhosis. *Lancet, The*, **2003**, 362, 53-61	40	269
260	Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. *Gastroenterology*, **2014**, 147, 1338-49.e5; quiz e15	13.3	265
259	Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. *Hepatology*, **2008**, 48, 1106-17	11.2	259
258	The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. *Digestive Diseases and Sciences*, **2005**, 50, 1734-40	4	243
257	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. *Gastroenterology*, **2015**, 149, 1804-1812.e4	13.3	235
256	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology*, **2019**, 69, 394-419	11.2	224
255	A revised natural history model for primary sclerosing cholangitis. *Mayo Clinic Proceedings*, **2000**, 75, 688-94	6.4	221
254	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. *Gastroenterology*, **2017**, 152, 1975-1984.e8	13.3	219
253	Cancer surveillance in patients with primary sclerosing cholangitis. *Hepatology*, **2011**, 54, 1842-52	11.2	204
252	A Revised Natural History Model for Primary Sclerosing Cholangitis. *Mayo Clinic Proceedings*, **2000**, 75, 688-694	6.4	203
251	Primary sclerosing cholangitis. *Hepatology*, **1999**, 30, 325-32	11.2	196
250	Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. *Hepatology*, **2007**, 45, 1547-54	11.2	195
249	Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. *Hepatology*, **1999**, 29, 644-7	11.2	186
248	Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. *Gastroenterology*, **1996**, 110, 1515-8	13.3	179
247	High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2011**, 106, 1638-45	0.7	177
246	Primary sclerosing cholangitis in children: a long-term follow-up study. *Hepatology*, **2003**, 38, 210-7	11.2	175

245	High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2001**, 96, 1558-62	0.7	172
244	A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. *New England Journal of Medicine*, **1990**, 322, 1419-24	59.2	169
243	Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 604-12	6.1	163
242	Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. *Journal of Hepatology*, **2003**, 39, 12-6	13.4	163
241	Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2001**, 96, 1059-66	0.7	161
240	Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?. *Hepatology*, **1992**, 15, 858-62	11.2	152
239	Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. *Hepatology*, **2000**, 31, 318-23	11.2	148
238	Review: nonalcoholic steatohepatitis. *Journal of Gastroenterology and Hepatology (Australia)*, **1997**, 12, 398-403	4	147
237	Small-duct primary sclerosing cholangitis: a long-term follow-up study. *Hepatology*, **2002**, 35, 1494-500	11.2	146
236	Metabolic and nutritional considerations in nonalcoholic fatty liver. *Hepatology*, **2000**, 32, 3-10	11.2	145
235	Time course of histological progression in primary biliary cirrhosis. *Hepatology*, **1996**, 23, 52-6	11.2	143
234	Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. *Liver Transplantation*, **2007**, 13, 1236-45	4.5	137
233	Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. *Liver International*, **1999**, 19, 115-21	7.9	135
232	Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. *Hepatology*, **2010**, 51, 174-80	11.2	134
231	Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. *Journal of Hepatology*, **2000**, 33, 537-42	13.4	133
230	Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. *Journal of Hepatology*, **2001**, 35, 316-23	13.4	131
229	In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. *American Journal of Gastroenterology*, **2002**, 97, 1138-42	0.7	130
228	Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. *Hepatology*, **2002**, 35, 409-13	11.2	128

227	Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. *Mayo Clinic Proceedings*, **1997**, 72, 1137-40	6.4	122
226	Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. *Digestive Diseases and Sciences*, **2001**, 46, 2347-52	4	118
225	Cost-effectiveness of ultrasound-guided liver biopsy. *Hepatology*, **1998**, 27, 1220-6	11.2	117
224	Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. *Hepatology*, **2005**, 42, 762-71	11.2	117
223	Oral budesonide in the treatment of primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2000**, 95, 2333-7	0.7	117
222	Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. *Hepatology*, **1999**, 30, 1381-6	11.2	112
221	Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. *American Journal of Gastroenterology*, **2007**, 102, 1244-50	0.7	110
220	Is there a role for liver biopsy in primary sclerosing cholangitis?. *American Journal of Gastroenterology*, **2003**, 98, 1155-8	0.7	109
219	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. *Gut*, **2016**, 65, 321-9	19.2	107
218	Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. *Hepatology*, **2012**, 55, 512-21	11.2	107
217	Antimitochondrial antibody-negative primary biliary cirrhosis. *American Journal of Gastroenterology*, **1995**, 90, 247-9	0.7	107
216	Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. *Hepatology*, **2007**, 46, 785-92	11.2	106
215	Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. *Digestive and Liver Disease*, **2011**, 43, 309-13	3.3	105
214	The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. *Hepatology*, **1999**, 29, 1643-8	11.2	104
213	Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. *Journal of Hepatology*, **1998**, 29, 729-35	13.4	102
212	Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. *Journal of Hepatology*, **2000**, 33, 537-542	13.4	99
211	Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. *Journal of Hepatology*, **1999**, 30, 830-5	13.4	99
210	Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. *American Journal of Gastroenterology*, **2002**, 97, 1191-7	0.7	98

209	Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. *American Journal of Therapeutics*, **2011**, 18, 198-205	1	96
208	The metabolic bone disease of primary sclerosing cholangitis. *Hepatology*, **1991**, 14, 257-261	11.2	95
207	Novel therapeutic targets in primary biliary cirrhosis. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 147-58	24.2	94
206	Changing nomenclature for PBC: From CirrhosisTo CholangitisS *Hepatology*, **2015**, 62, 1620-2	11.2	92
205	Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 434-9.e1	6.9	92
204	Recent advances in the development of farnesoid X receptor agonists. *Annals of Translational Medicine*, **2015**, 3, 5	3.2	92
203	Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. *American Journal of Gastroenterology*, **2009**, 104, 83-8	0.7	90
202	Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. *Hepatology*, **2004**, 40, 39-45	11.2	90
201	Fat-soluble vitamin levels in patients with primary biliary cirrhosis. *American Journal of Gastroenterology*, **2001**, 96, 2745-50	0.7	90
200	Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?. *Hepatology*, **1995**, 21, 389-392	11.2	89
199	Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. *Hepatology*, **1997**, 26, 22-6	11.2	86
198	Primary sclerosing cholangitis. *Inflammatory Bowel Diseases*, **2005**, 11, 62-72	4.5	85
197	Incidence of cancer in primary biliary cirrhosis: the Mayo experience. *Hepatology*, **1999**, 29, 1396-8	11.2	85
196	Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. *American Journal of Gastroenterology*, **2010**, 105, 345-53	0.7	84
195	Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. *American Journal of Gastroenterology*, **2011**, 106, 2023-8	0.7	83
194	Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?. *Hepatology*, **1995**, 21, 389-92	11.2	83
193	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. *Hepatology*, **2016**, 64, 189-99	11.2	81
192	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. *Journal of Hepatology*, **2019**, 71, 357-365	13.4	80

191	Bone disease in patients with primary sclerosing cholangitis. *Gastroenterology*, **2011**, 140, 180-8	13.3	80
190	Natural history of pruritus in primary biliary cirrhosis. *Clinical Gastroenterology and Hepatology*, **2003**, 1, 297-302	6.9	80
189	Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. *New England Journal of Medicine* , **2007**, 357, 1524-9	59.2	78
188	The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. *American Journal of Gastroenterology*, **1991**, 86, 57-61	0.7	77
187	B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. *Hepatology*, **2009**, 50, 1893-903	11.2	75
186	Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. *Hepatology*, **1999**, 29, 39-43	11.2	70
185	A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2000**, 95, 2338-42	0.7	68
184	The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. *Hepatology*, **1995**, 22, 1158-62	11.2	67
183	Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. *Journal of Clinical Gastroenterology*, **1995**, 20, 215-9	3	65
182	Role of the microbiota and antibiotics in primary sclerosing cholangitis. *BioMed Research International*, **2013**, 2013, 389537	3	64
181	Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. *Journal of Hepatology*, **2000**, 33, 878-82	13.4	64
180	Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. *Scandinavian Journal of Gastroenterology*, **2014**, 49, 901-8	2.4	63
179	Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. *Clinical Gastroenterology and Hepatology*, **2004**, 2, 1116-22	6.9	62
178	Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. *Hepatology*, **2000**, 32, 897-900	11.2	61
177	Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. *American Journal of Gastroenterology*, **1996**, 91, 511-5	0.7	60
176	High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 1185-92	6.1	59
175	Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2012**, 107, 431-9	0.7	59
174	Primary sclerosing cholangitis. *Canadian Journal of Gastroenterology & Hepatology*, **2008**, 22, 689-98		58

173	Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2005**, 100, 308-12	0.7	58
172	Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. *Gut*, **1995**, 36, 935-8	19.2	57
171	When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?. *Clinical Gastroenterology and Hepatology*, **2003**, 1, 89-95	6.9	56
170	Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. *Hepatology*, **2018**, 67, 2338-2351	11.2	56
169	Changing nomenclature for PBC: From ŠirrhosisŠto ŠholangitisŠ *Journal of Hepatology*, **2015**, 63, 1285-7	13.4	55
168	Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. *Digestive Diseases and Sciences*, **1999**, 44, 602-7	4	55
167	Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis. *Hepatology*, **1988**, 8, 668-76	11.2	54
166	The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study. *Hepatology*, **1995**, 22, 1158-1162	11.2	53
165	Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis. *Hepatology*, **1987**, 7, 884-8	11.2	52
164	Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. *Hepatology*, **2008**, 48, 1149-56	11.2	51
163	Interactions Between Chronic Liver Disease and Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **1997**, 3, 288-302	4.5	49
162	Primary sclerosing cholangitis: a review and update on therapeutic developments. *Expert Review of Gastroenterology and Hepatology*, **2013**, 7, 103-14	4.2	46
161	Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. *Liver International*, **2012**, 32, 790-5	7.9	45
160	Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 52-6	6.9	45
159	Pirfenidone in the treatment of primary sclerosing cholangitis. *Digestive Diseases and Sciences*, **2002** , 47, 157-61	4	45
158	Unmet clinical need in autoimmune liver diseases. *Journal of Hepatology*, **2015**, 62, 208-18	13.4	44
157	Clinical features and management of primary sclerosing cholangitis. *World Journal of Gastroenterology*, **2008**, 14, 3338-49	5.6	44
156	Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. *World Journal of Gastroenterology*, **2019**, 25, 659-671	5.6	44

155	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. *American Journal of Gastroenterology*, **2018**, 113, 254-264	0.7	44
154	Interactions Between Chronic Liver Disease and Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **1997**, 3, 288-302	4.5	43
153	Development of autoimmune hepatitis in primary biliary cirrhosis. *Liver International*, **2007**, 27, 1086-90	7.9	43
152	Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. *Alimentary Pharmacology and Therapeutics*, **2008**, 28, 886-94	6.1	42
151	Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 259-64	6.9	42
150	Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 886-895	6.1	41
149	Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. *Digestive Diseases and Sciences*, **2006**, 51, 1985-91	4	41
148	Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1342-1350.e1	6.9	40
147	Pathogenesis and management of pruritus in cholestatic liver disease. *Journal of Gastroenterology and Hepatology (Australia)*, **2012**, 27, 1150-8	4	40
146	Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. *American Journal of Therapeutics*, **2017**, 24, e56-e63	1	39
145	Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. *Mayo Clinic Proceedings*, **1994**, 69, 923-9	6.4	39
144	Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?. *American Journal of Gastroenterology*, **2001**, 96, 3152-7	0.7	35
143	Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. *Journal of Hepatology*, **2002**, 36, 8-13	13.4	35
142	Mycophenolate Mofetil for the Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid. *Journal of Clinical Gastroenterology*, **2005**, 39, 838	3	34
141	A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis. *American Journal of Therapeutics*, **2017**, 24, e167-e176	1	33
140	Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease. *Hepatology*, **2000**, 32, 924-9	11.2	33
139	The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 255-65	6.1	32
138	Fatigue in primary biliary cirrhosis. *Nature Reviews Gastroenterology and Hepatology*, **2010**, 7, 313-9	24.2	32

137	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. *American Journal of Gastroenterology*, **2020**, 115, 1066-1074	0.7	31
136	AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2416-2422	6.9	31
135	Varices in early histological stage primary biliary cirrhosis. *Journal of Clinical Gastroenterology*, **2011**, 45, e66-71	3	31
134	Old and new treatments for primary biliary cholangitis. *Liver International*, **2017**, 37, 490-499	7.9	30
133	Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. *Clinics in Liver Disease*, **2003**, 7, 901-10	4.6	30
132	Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. *Journal of Clinical Gastroenterology*, **2017**, 51, e11-e16	3	29
131	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. *Alimentary Pharmacology and Therapeutics*, **2019**, 50, 1127-1136	6.1	29
130	Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’. *Clinics and Research in Hepatology and Gastroenterology*, **2015**, 39, e57-9	2.4	29
129	Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. *Digestive Diseases and Sciences*, **2008**, 53, 1716-20	4	29
128	Obeticholic acid for the treatment of primary biliary cholangitis. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 1809-15	4	29
127	Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications. *Annals of Hepatology*, **2017**, 16, 835-841	3.1	28
126	The natural history of primary biliary cirrhosis. *Seminars in Liver Disease*, **2014**, 34, 329-33	7.3	28
125	Antimitochondrial antibody-negative primary biliary cirrhosis. *Gastroenterology Clinics of North America*, **2008**, 37, 479-84, viii	4.4	28
124	Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. *Journal of Clinical Gastroenterology*, **2003**, 37, 183-5	3	28
123	An update on cancer risk and surveillance in primary sclerosing cholangitis. *Liver International*, **2017**, 37, 1103-1109	7.9	27
122	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2076-2084.e2	6.9	27
121	Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. *Hepatology*, **2008**, 47, 133-42	11.2	27
120	Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. *Annals of Hepatology*, **2016**, 15, 246-53	3.1	27

119	Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1333-1341.e6	6.9	26
118	Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 365-72	4	26
117	Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. *American Journal of Gastroenterology*, **1996**, 91, 2314-7	0.7	26
116	Primary biliary cirrhosis in adults. *Expert Review of Gastroenterology and Hepatology*, **2014**, 8, 427-33	4.2	25
115	Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. *Journal of Clinical Gastroenterology*, **2005**, 39, 168-71	3	24
114	Current research on the treatment of primary sclerosing cholangitis. *Intractable and Rare Diseases Research*, **2015**, 4, 1-6	1.4	23
113	Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. *Scandinavian Journal of Gastroenterology*, **2016**, 51, 745-52	2.4	22
112	Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. *Hepatology*, **2018**, 68, 1174-1188	11.2	21
111	Pregnancy in a patient with primary sclerosing cholangitis. *Journal of Clinical Gastroenterology*, **2002**, 35, 353-5	3	21
110	Clinical implications of serial versus isolated biliary fluorescence in situ hybridization (FISH) polysomy in primary sclerosing cholangitis. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 377-381	2.4	20
109	Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. *Liver International*, **2018**, 38, 399-411	7.9	20
108	Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 182-5	6.9	20
107	Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. *Scandinavian Journal of Gastroenterology*, **2019**, 54, 633-639	2.4	19
106	Neoplasia in the ileoanal pouch following colectomy in patients with ulcerative colitis and primary sclerosing cholangitis. *Journal of Crohn's and Colitis*, **2014**, 8, 1294-9	1.5	19
105	Antibiotics for the treatment of primary sclerosing cholangitis. *American Journal of Therapeutics*, **2011**, 18, 261-5	1	19
104	Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. *Liver Transplantation*, **1999**, 5, 269-74		19
103	The natural history of abdominal pain associated with primary biliary cirrhosis. *American Journal of Gastroenterology*, **1994**, 89, 1840-3	0.7	18
102	Dominant strictures in primary sclerosing cholangitis: A multicenter survey of clinical definitions and practices. *Hepatology Communications*, **2018**, 2, 836-844	6	17

101	Clinical management of autoimmune biliary diseases. *Journal of Autoimmunity*, **2013**, 46, 88-96	15.5	17
100	Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. *Liver International*, **2010**, 30, 251-8	7.9	17
99	Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis. *Pediatric Gastroenterology, Hepatology and Nutrition*, **2016**, 19, 210-213	2.3	16
98	The autologous mixed lymphocyte reaction in primary biliary cirrhosis: analysis of activation and blastogenesis of autoreactive T lymphocytes. *Hepatology*, **1988**, 8, 1555-9	11.2	15
97	Advances in primary sclerosing cholangitis. *The Lancet Gastroenterology and Hepatology*, **2016**, 1, 68-77	18.8	15
96	Emerging drugs for the treatment of Primary Biliary Cholangitis. *Expert Opinion on Emerging Drugs*, **2016**, 21, 39-56	3.7	14
95	New treatment strategies for primary sclerosing cholangitis. *Digestive Diseases*, **2011**, 29, 113-6	3.2	14
94	Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis. *Journal of Analytical Oncology*, **2012**, 1, 50-55		14
93	Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. *Scandinavian Journal of Gastroenterology*, **2020**, 55, 941-950	2.4	14
92	Early primary biliary cirrhosis: just delayed or different?. *Hepatology*, **1997**, 26, 239-41	11.2	13
91	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. *Gut*, **2020**, 69, 1502-1509	19.2	13
90	Update on pharmacotherapies for cholestatic liver disease. *Hepatology Communications*, **2017**, 1, 7-17	6	12
89	Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications. *Alimentary Pharmacology and Therapeutics*, **2009**, 30, 816-25	6.1	12
88	Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis. *Journal of Clinical Gastroenterology*, **2021**, 55, 449-457	3	12
87	The Microbiome and Primary Sclerosing Cholangitis. *Seminars in Liver Disease*, **2016**, 36, 340-348	7.3	12
86	Emerging treatments for primary sclerosing cholangitis. *Expert Review of Gastroenterology and Hepatology*, **2017**, 11, 451-459	4.2	11
85	Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. *Hepatology*, **2021**, 73, 1868-1881	11.2	11
84	An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. *Journal of Gastroenterology*, **2020**, 55, 523-532	6.9	10

83	Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 90-109	6.1	10
82	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 684-692.e6	6.9	10
81	Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. *Digestive Diseases and Sciences*, **2010**, 55, 476-83	4	9
80	The management of autoimmunity in patients with cholestatic liver diseases. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 73-91	4.2	8
79	Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. *Annals of Hepatology*, **2014**, 13, 384-389	3.1	8
78	Current and promising therapy for primary biliary cholangitis. *Expert Opinion on Pharmacotherapy*, **2019**, 20, 1161-1167	4	7
77	Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. *Annals of Hepatology*, **2014**, 13, 384-9	3.1	7
76	Primary sclerosing cholangitis in children versus adults: lessons for the clinic. *Expert Review of Gastroenterology and Hepatology*, **2018**, 12, 1025-1032	4.2	7
75	Primary biliary cirrhosis: safety and benefits of established and emerging therapies. *Expert Opinion on Drug Safety*, **2015**, 14, 1435-44	4.1	6
74	Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. *American Journal of Gastroenterology*, **2020**, 115, 262-270	0.7	6
73	Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. *Clinical Liver Disease*, **2020**, 15, 1-2	2.2	6
72	Chronic cholestasis in a young man. *Hepatology*, **1994**, 20, 1351-1355	11.2	6
71	Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment. *Gastroenterology and Hepatology*, **2018**, 14, 293-304	0.7	6
70	The metabolic bone disease of primary sclerosing cholangitis **1991**, 14, 257		6
69	The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience. *Journal of Gastroenterology*, **2020**, 55, 1087-1097	6.9	6
68	Cancer risk, screening and surveillance in primary sclerosing cholangitis. *Minerva Gastroenterologica E Dietologica*, **2019**, 65, 214-228	1.6	5
67	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1688-1697.e14	6.9	5
66	Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: Is It Really the Same Disease?. *Clinics in Liver Disease*, **2018**, 22, 589-601	4.6	4

65	Investigational drugs in phase II clinical trials for primary biliary cholangitis. *Expert Opinion on Investigational Drugs*, **2017**, 26, 1115-1121	5.9	4
64	Medical treatment for primary sclerosing cholangitis: risk versus benefit. *Hepatology*, **2000**, 32, 871-2	11.2	4
63	Management of primary biliary cirrhosis: from diagnosis to end-stage disease. *Current Gastroenterology Reports*, **2000**, 2, 94-8	5	4
62	Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance. *Gastroenterology and Hepatology*, **2018**, 14, 427-432	0.7	4
61	Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis **2017**, 145-152		4
60	Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta-analysis. *Liver International*, **2021**, 41, 2418-2426	7.9	4
59	Pregnancy in primary sclerosing cholangitis. *Gut*, **2011**, 60, 1027-8	19.2	3
58	Colchicine and ursodeoxycholic acid for primary biliary cirrhosis: emerging results. *Gastroenterology* , **1995**, 108, 1592-4	13.3	3
57	Chronic cholestasis in a young man **1994**, 20, 1351		3
56	Time course of histological progression in primary biliary cirrhosis **1996**, 23, 52		3
55	Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?. *Translational Research*, **2010**, 155, 120-2	11	2
54	Safety of fibrates in cholestatic liver diseases. *Liver International*, **2021**, 41, 1335-1343	7.9	2
53	Potential Association of Doxycycline With the Onset of Primary Sclerosing Cholangitis: A Case Series. *American Journal of Therapeutics*, **2019**,	1	2
52	An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis. *Expert Opinion on Orphan Drugs*, **2014**, 2, 545-556	1.1	1
51	Vascular Diseases of the Liver **2010**, 261-274		1
50	Medical management of chronic cholestatic liver diseases. *Canadian Journal of Gastroenterology & Hepatology*, **2000**, 14 Suppl D, 93D-98D		1
49	Primary Biliary Cirrhosis. *Current Treatment Options in Gastroenterology*, **1999**, 2, 473-480	2.5	1
48	Recent developments in the management of idiopathic cholestatic liver disease. *Annals of Gastroenterology*, **2012**, 25, 317-326	2.2	1

47	Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. *European Journal of Gastroenterology and Hepatology*, **2020**, 33,	2.2	1
46	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. *American Journal of Gastroenterology*, **2021**, 116, 1514-1522	0.7	1
45	Novel treatments in primary sclerosing cholangitis. *Clinical Liver Disease*, **2016**, 8, 132-135	2.2	1
44	Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent. *Clinical Journal of Gastroenterology*, **2021**, 14, 684-689	1.1	1
43	Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA. *Digestive Diseases and Sciences*, **2021**, 1	4	1
42	A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis.. *Hepatology Communications*, **2022**,	6	1
41	The possible link between the thyroid and autoimmune liver diseases: reply. *Liver International*, **2010**, 30, 1240-1241	7.9	0
40	Emerging therapeutic targets for primary sclerosing cholangitis. *Expert Opinion on Orphan Drugs*, **2018**, 6, 393-401	1.1	
39	Biliary Atresia and Cystic Fibrosis: Transitioning Care from Pediatrics to Internal Medicine **2010**, 164-171		
38	Acute Viral Hepatitis: Hepatitis A, Hepatitis E, and Other Viruses **2010**, 173-185		
37	Hepatitis B and C **2010**, 186-199		
36	Liver Transplantation: Early and Long Term Management and Complications **2010**, 327-346		
35	Bacterial and Other Non-Viral Infections of the Liver **2010**, 200-215		
34	Immunology of the Liver and Mechanisms of Inflammation **2010**, 17-22		
33	Cancer of the Gall Bladder and Biliary Tree **2010**, 374-382		
32	Assessment of Abnormal Liver Injury Tests **2010**, 32-37		
31	Endoscopic Techniques in Management of the Liver and Biliary Tree: Endoscopic Ultrasonography **2010**, 71-79		
30	Gall Stones, Gall-Bladder Polyps and Their Complications: Epidemiology, Pathogenesis, Diagnosis, and Management **2010**, 347-364		

29 Indications and Selection of Patients for Liver Transplantation **2010**, 297-304

28 Endoscopic Techniques in Management of the Liver and Biliary Tree: Upper Gastrointestinal Endoscopy **2010**, 55-60

27 Liver Mass Found on Abdominal Imaging **2010**, 95-104

26 Autoimmune Liver Diseases **2010**, 250-260

25 Metabolic Liver Diseases **2010**, 216-223

24 Hepatic Manifestations of Systemic Diseases **2010**, 288-295

23 Liver Biopsy and Paracentesis **2010**, 80-86

22 Right Upper Quadrant Abdominal Pain **2010**, 105-112

21 Hepatic Complications of Bone Marrow Transplantation **2010**, 275-287

20 Jaundice and Pruritus: A Diagnostic Approach **2010**, 87-94

19 Hepatic Steatosis and Non-Alcoholic Fatty Liver Disease **2010**, 224-234

18 What Hepatologists Should Know about Liver Transplant Surgery **2010**, 305-316

17 Approach to History Taking and Physical Examination in Liver and Biliary Disease **2010**, 23-31

16 Drug-Induced Liver Injury **2010**, 235-242

15 Imaging of the Liver and Biliary Tree **2010**, 38-54

14 The Liver and Biliary Apparatus: Basic Structural Anatomy and Variations **2010**, 1-16

13 Biliary Strictures and Leaks **2010**, 383-392

12 Functional Gall-Bladder and Sphincter of Oddi Disorders **2010**, 365-373

List of Publications

11	Immunosuppression in Liver Transplantation **2010**, 317-326	
10	Pregnancy and Liver Disease **2010**, 152-163	
9	Reply: Diagnostic Utility of Chromosome 17 and p16 Abnormalities in Fluorescence In Situ Hybridization Tests in Primary Sclerosing Cholangitis. *Hepatology*, **2010**, 52, 394-395	11.2
8	Commentary: Primary Sclerosing Cholangitis **2015**, 61-63	
7	Endoscopic Techniques in Management of the Liver and Biliary Tree: Endoscopic Retrograde Cholangiopancreatography and Biliary Manometry61-70	
6	Is there Still a Role for Ursodeoxycholic Acid Treatment in Patients with Inflammatory Bowel Disease Associated with Primary Sclerosing Cholangitis?156-158	
5	Targets and investigative treatments for primary biliary cholangitis. *Expert Opinion on Orphan Drugs* , **2016**, 4, 1011-1020	1.1
4	Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients. *Expert Opinion on Orphan Drugs*, **2021**, 9, 53-66	1.1
3	Primary biliary cirrhosis. *Revista De Gastroenterología De México*, **1995**, 60, S75-7	0.7
2	Primary sclerosing cholangitis. *Revista De Gastroenterología De México*, **1995**, 60, S78-80	0.7
1	Linking medical education and patient care. *Minnesota Medicine*, **2010**, 93, 32, 34	0.3